Government-Owned Inventions; Availability for Licensing and/or Co-Development, 81150-81151 [2016-27613]

Download as PDF 81150 Federal Register / Vol. 81, No. 222 / Thursday, November 17, 2016 / Notices Emphasis Panel; NIAID Resource-Related Research Projects (R24). Date: December 12, 2016. Time: 2:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Room 3E73, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Audrey O. Lau, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 240–669–2081, audrey.lau@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: November 14, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–27675 Filed 11–16–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings asabaliauskas on DSK3SPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Phase II In-person Interview: NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1). Date: December 12, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, (301) 827–5820, hiromi.ono@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; VerDate Sep<11>2014 21:24 Nov 16, 2016 Jkt 241001 Laboratory and Diagnostic Tools to Advance Microbiome-Brain Research (R41/R42/R43/ R44). Date: December 13, 2016. Time: 10:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, Bethesda, MD 20814. Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301–827–5819, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Multisite Clinical Trials SEP II. Date: December 14, 2016. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827–5817, mcguireso@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: November 14, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–27677 Filed 11–16–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing and/or CoDevelopment AGENCY: National Institutes of Health. HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development. ADDRESSES: Invention Development and Marketing Unit, Technology Transfer SUMMARY: PO 00000 Frm 00098 Fmt 4703 Sfmt 4703 Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850–9702. FOR FURTHER INFORMATION CONTACT: Information on licensing and codevelopment research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD, 20850–9702, Tel. 240–276–5515 or email ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Title of invention: Gene Signature Predictive of Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization (TACE). Keywords: Diagnostic, Biomarker, Prognostic, Hepatocellular Carcinoma, Patient Stratification, TACE, HCC. Description of Technology: Hepatocellular Carcinoma (HCC) is one of the most common cancers worldwide with largely unfavorable outcomes due to a lack of effective treatment options for patients in the later state of disease. The gold standard of care for HCC patients with intermediate to locally advanced tumors is transcatheter arterial chemoembolization (TACE), a procedure whereby the tumor is targeted both with local chemotherapy and restriction of local blood supply. TACE procedures are often not effective, however, and a need exists to identify patients that will respond to TACE. Scientists in NCI’s Laboratory of Human Carcinogenesis have identified a 14-gene signature that is predictive of response to TACE. The ‘‘TACE Navigator Gene Signature Assay,’’ based on a Nanostring Technologies platform, is useful in identifying those HCC patients, prior to treatment, who will respond to and have the greatest survival benefit following TACE. The signature can also identify patients who need additional/alternative therapeutic modalities. This invention is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S., in accordance with 35 U.S.C. 209 and 37 CFR part 404, to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development. E:\FR\FM\17NON1.SGM 17NON1 Federal Register / Vol. 81, No. 222 / Thursday, November 17, 2016 / Notices Potential Commercial Applications: • Prognostic test for HCC patient response to TACE procedure • Companion diagnostic for TACE procedure Value Proposition: • First in class prognostic diagnostic for frontline therapy in highly prevalent HCC Development Stage: Basic (Target ID). Inventor(s): Xin Wei Wang, Ph.D. and Valerie Miller, Ph.D. (NCI). Intellectual Property: HHS Reference No. E–101–2016 U.S. Provisional Application 62/292,789 (HHS Reference No. E–101–2016/0– US–01) filed February 8, 2016 entitled ‘‘Gene Signature Predictive of Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization (TACE)’’ Related Technologies: NIH Reference No. E–024–2009 entitled ‘‘Gene Signature for Predicting Solid Tumors Patient Response’’. Collaboration Opportunity: Researchers at the NCI seek licensing and/or co-development research collaborations for the commercialization of a companion diagnostic for HCC patients undergoing TACE procedures. Contact Information: Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email: john.hewes@ nih.gov. Dated: November 8, 2016. John D. Hewes, Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute. individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Rapid Assessment of Zika Virus (ZIKV) Complications (R21). Date: December 9, 2016. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Raymond R. Schleef, Ph.D., Senior Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3E61, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5019, schleefrr@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: November 14, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–27674 Filed 11–16–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF THE INTERIOR Fish and Wildlife Service [FWS–R1–ES–2016–N185; FXES11120100000–167–FF01E00000] [FR Doc. 2016–27613 Filed 11–16–16; 8:45 am] Final Habitat Conservation Plan and Supplemental Final Environmental Impact Statement; Na Pua Makani Wind Energy Project, Oahu, Hawaii BILLING CODE 4140–01–P AGENCY: Fish and Wildlife Service, Interior. ACTION: Notice of availability; notice of permit application; request for comments. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health asabaliauskas on DSK3SPTVN1PROD with NOTICES National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning VerDate Sep<11>2014 21:24 Nov 16, 2016 We, the U.S. Fish and Wildlife Service (Service), received an incidental take permit application from Na Pua Makani Power Partners, LLC, pursuant to the Endangered Species Act of 1973, as amended (ESA). The requested permit would authorize the take of one threatened and six endangered species caused by covered activities associated with a wind energy generation project on the island of Oahu, Hawaii. The permit application included the proposed Na Pua Makani Wind Energy Project Habitat Conservation Plan (HCP), which described the activities that may result in the incidental taking of listed species, and the measures the applicant will take SUMMARY: Jkt 241001 PO 00000 Frm 00099 Fmt 4703 Sfmt 4703 81151 to minimize, mitigate, and monitor for adverse impacts to the covered species. The applicant modified the proposed action in the HCP in response to public comments and the modified HCP is available for public review pursuant to this notice. The Service also announces the availability of a Supplemental Final Environmental Impact Statement (SEIS) addressing the modified proposed action in accordance with the requirements of the National Environmental Policy Act of 1969 (NEPA). If issued, the ITP would authorize incidental take of the covered species that may occur as a result of the construction and operation of the Na Pua Makani Wind Energy Project (Project) over a 21-year period. We are making the permit application package, including the modified HCP and SEIS, available for public review and comment. DATES: To ensure consideration, written comments must be received from interested parties no later than December 19, 2016. The Service’s decision on issuance of an ITP will occur no sooner than 30 days after the publication of the U.S. Environmental Protection Agency’s notice of the SEIS in the Federal Register and will be documented in a Record of Decision (ROD). (For information about the EPA notice, see The Environmental Protection Agency’s Role in the EIS Process under SUPPLEMENTARY INFORMATION.) ADDRESSES: To request further information or submit written comments, please use one of the following methods, and note that your information request or comments are in reference to the Na Pua Makani Wind Energy Project HCP. • Internet: Documents may be viewed and downloaded on the Internet at http://www.fws.gov/pacificislands/. • Email: NaPuaMakanihcp@fws.gov. • U.S. Mail: You may obtain a compact disk with electronic copies of these documents by writing to Mary Abrams, Field Supervisor; U.S. Fish and Wildlife Service; Pacific Islands Fish and Wildlife Office; 300 Ala Moana Boulevard, Room 3–122; Honolulu, HI 96850. • Telephone: Call 808–792–9400 during regular business hours. FOR FURTHER INFORMATION CONTACT: Ms. Jodi Charrier or Mr. Aaron Nadig, U.S. Fish and Wildlife Service (see ADDRESSES); by telephone 808–792– 9400; or by email at NaPuaMakanihcp@ fws.gov. If you use a telecommunications device for the deaf, please call the Federal Relay Service at 800–877–8339. E:\FR\FM\17NON1.SGM 17NON1

Agencies

[Federal Register Volume 81, Number 222 (Thursday, November 17, 2016)]
[Notices]
[Pages 81150-81151]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-27613]


-----------------------------------------------------------------------

 DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing and/or 
Co-Development

AGENCY: National Institutes of Health. HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. to achieve expeditious commercialization of results of federally-
funded research and development. Foreign patent applications are filed 
on selected inventions to extend market coverage for companies and may 
also be available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD, 20850-9702, Tel. 240-276-5515 or email 
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Gene Signature Predictive of Hepatocellular 
Carcinoma Response to Transcatheter Arterial Chemoembolization (TACE).
    Keywords: Diagnostic, Biomarker, Prognostic, Hepatocellular 
Carcinoma, Patient Stratification, TACE, HCC.
    Description of Technology: Hepatocellular Carcinoma (HCC) is one of 
the most common cancers worldwide with largely unfavorable outcomes due 
to a lack of effective treatment options for patients in the later 
state of disease. The gold standard of care for HCC patients with 
intermediate to locally advanced tumors is transcatheter arterial 
chemoembolization (TACE), a procedure whereby the tumor is targeted 
both with local chemotherapy and restriction of local blood supply. 
TACE procedures are often not effective, however, and a need exists to 
identify patients that will respond to TACE.
    Scientists in NCI's Laboratory of Human Carcinogenesis have 
identified a 14-gene signature that is predictive of response to TACE. 
The ``TACE Navigator Gene Signature Assay,'' based on a Nanostring 
Technologies platform, is useful in identifying those HCC patients, 
prior to treatment, who will respond to and have the greatest survival 
benefit following TACE. The signature can also identify patients who 
need additional/alternative therapeutic modalities.
    This invention is owned by an agency of the U.S. Government and is 
available for licensing and/or co-development in the U.S., in 
accordance with 35 U.S.C. 209 and 37 CFR part 404, to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

[[Page 81151]]

    Potential Commercial Applications:

 Prognostic test for HCC patient response to TACE procedure
 Companion diagnostic for TACE procedure

    Value Proposition:

 First in class prognostic diagnostic for frontline therapy in 
highly prevalent HCC

    Development Stage: Basic (Target ID).
    Inventor(s): Xin Wei Wang, Ph.D. and Valerie Miller, Ph.D. (NCI).
    Intellectual Property:

HHS Reference No. E-101-2016
U.S. Provisional Application 62/292,789 (HHS Reference No. E-101-2016/
0-US-01) filed February 8, 2016 entitled ``Gene Signature Predictive of 
Hepatocellular Carcinoma Response to Transcatheter Arterial 
Chemoembolization (TACE)''

    Related Technologies: NIH Reference No. E-024-2009 entitled ``Gene 
Signature for Predicting Solid Tumors Patient Response''.
    Collaboration Opportunity: Researchers at the NCI seek licensing 
and/or co-development research collaborations for the commercialization 
of a companion diagnostic for HCC patients undergoing TACE procedures.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: john.hewes@nih.gov.

    Dated: November 8, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-27613 Filed 11-16-16; 8:45 am]
 BILLING CODE 4140-01-P